Fermentation of Micromonospora purpurea NRRL 2953 affords, as the major products, the important antibiotics gentamicins C1, C2 and C1a , (gentamicin C complex)2) as well as a host of minor components.') During the screening of this organism, in search of improved gentamicin producers, a novel variant, designated M. purpurea var. JI-33, was isolated. The strain, obtained by multiple nitrosoguanidine treatments and repeated strain selection, was found to possess similar morphology to that already described for gentamicin-producing strains of M.
purpurea.1) The new strain, JI-33, however, produced an aminoglycoside antibiotic complex different from the normal gentamicin fermentations. The major product isolated from the JI-33 fermentation broth proved to be gentamicin C1a, (1);1,5,6) gentamicins C2 (2) and C1 (3) were not observed. A minor but substantial constituent of the fermentation, migrating similarly to gentamicin C2 on chromatography, was isolated and designated antibiotic JI-33B. Smaller amounts of more polar components were also observed. Several years ago a very minor component of the gentamicin fermentation was isolated in our laboratories using countercurrent distribution and was named gentamicin C2a• Evidence suggested that this compound was I Gentamicin C1a has been adopted for this antibiotic in view of its structural similarity to the other gentamicin C components. The chromatographic mobilities of gentamicins C1, C2, C2b and C1a in several systems are shown in Table 1 . A paper chromatographic system8) ( Table 1 , system 4) was found which differentiated all the gentamicin C components.
Gentamicin C,b was obtained as a white amorphous solid; its molecular weight by mass spectrometry was 463, the same as gentamicin C2. Principal fragments in its mass spectrum indicated the presence of garosamine, 2-deoxystreptamine and a third sugar giving rise to a prominent ion at m/e 143 (5)9> (see Experimental section). A characteristic feature of the mass spectrum was a relatively intense peak at m/e 433; no analogous peak was observed in the mass spectrum of gentamicin C1a (1). This peak is thought to arise by the loss of a CH,N fragment from the molecular ion or a CH,NH, fragment from the MH+ ion. The pmr spectrum of gentamicin C,, base is shown in Fig.   1A , and of the acidified solution in Fig. 113 . In view of the structural relationships of gentamicins C1, C2 and C1a , which differ only in the degree of methylation of the 2,6-diaminosugar (purpurosamine5)) unit, these data suggested that gentamicin C2b was 6'-N-methylgentamicin C1a, (6) . This was supported by the cmr spectral data shown in Table 2 . The assignments of resonances for gentamicin C1a have been discussed previously.10) Inspection of the data in Table 2 proposed for this material, mainly on the basis of its mass spectrum, despite the fact that the pmr data given in that report11) clearly show that the material isolated was a mixture. The in vitro antibacterial activity of gentamicin C2b is shown in Table 3 in comparison to that of gentamicin C complex. The M.I.C. values for the two substances are similar. Experimental FOURIER transform NMR spectra were taken in D,O solution using a Varian XL-100-15 instrument equipped with a 620L computer. PMR shifts are reported downfield from sodium 2,2-dimethyl-2-silapentane sulfonate using the HOD line (3 4.68 ppm) as an internal reference.
CMR shifts were referenced to internal dioxane and are reported downfield relative to TMS using the relationship 8TMS C=Sdiox c+67.4ppm. Mass spectra were obtained using a Varian MAT CH5 spectrometer at 70 eV with a probe temperature of 150-250°C. The direct inlet technique was used. Optical rotations were recorded in aqueous solution using a Bendix model 143 automatic polarimeter. Chromatography was carried out on silica gel (70-230 mesh, E. Merck, Darmstadt, W. Germany).
Fermentation and Isolation of Antibiotic JI-33 Complex. Fermentation of strain JI-33 was carried out in shake-flasks and 10 liter fermentors under aerobic conditions. The inoculum was prepared in a medium consisting of: Bacto beef extract (3 g), Bacto tryptone (5 g), Bacto dextrose (1 g), soluble starch (24 g), yeast extract (5 g), calcium carbonate (1 g), Difco broth (15 g) and soft water (1 liter). A vigorously growing 48-hour culture was an excellent inoculum; best results were obtained with a 10 % inoculum for the production stage. The production medium consisted of: potatoe dextrin (50 g), dextrose (5 g) calcium carbonate (1 g), soybean meal (35 g) and soft water (1 liter). The pH was adjusted to 7.2 using sodium hydroxide solution and GE-60 was added as an antifoam. After sterilization in an autoclave fermentations were carried out at 3334°C with agitation at 400-500 rpm. The production peak (120-144 hours) was established by periodic sampling of the fermentation broth and assaying versus Staphylococcus aureus ATCC 6538-P according to the disc-plate assay procedure Of ODEN et al.13) using gentamicin as the standard. Peak titers of 800-1,400 mcg/ml * We have experienced difficulty, in certain cases, in obtaining reproducible optical rotation values for aminoglycoside-aminocyclitol antibiotic bases. We have attributed this to (1) difficulty in completely removing water from the sample by vacuum drying and the hygroscopic nature of the materials which makes accurate weighings difficult; (2) problems due to carbonation of the samples with atmospheric CO2. As an example, chromatographically homogeneous gentamicin C2b, after normal isolation and drying has given rotations of +145-*148°. However, a sample which was carefully decarbonated by passage through a strongly basic ion exchange resin, collecting only the first part of the eluate, with subsequent handling under nitrogen, gave an optical rotation of +165o (average of two determinations) (see Experimental section).
THE JOURNAL OF ANTIBIOTICS JAN. 1975 were obtained. At harvest the whole broth was acidified to pH 2 with 12 N sulfuric acid and the mycelium was removed by filtration. The filtrate was neutralized with concentrated ammonium hydroxide and calcium ions were removed by the addition of a saturated solution of oxalic acid followed by filtration of the precipitated calcium oxalate. After reneutralization the filtrate was passed through an AmberliteR IRC-72 resin (NH+4 cycle), the resin was washed with distilled water and the antibiotic complex eluted with 2 N ammonium hydroxide. The eluate we concentrated to low volume in i acuo and decolorized by passage through an Amberlite5l IRA-458 resin followed by elution with distilled water. The eluate was concentrated in lacuo and lyophilized to give crude antibiotic JI-33 complex (yield 300600 mcg/ml, with potency of 500700 mcg/mg vs gentamicin).
Purification of Antibiotics from JI-33 Complex. The crude antibiotic complex was chromatographed over silica gel using the lower phase of a 2:1:1 mixture of chloroform-isopropanol-concentrated ammonium hydroxide. Fractions were monitored by thin-layer chromatography. Gentamicin C2b (6) was eluted first and comprised 5 -10 °o by weight of the crude antibiotic complex. Further elution gave gentamicin C1a (1), comprising 25 ~50 % by weight of the crude antibiotic complex. Gentamicin C1a was identified by chromatographic, spectral and microbiological comparisons with an authentic sample.
Gentamicin C2b.
Final purification of this material was effected by rechromatography of a sample (1.2g) over 120g of silica gel, eluting with the lower phase of a 2:1:1 chloroform-methanol-ION ammonium hydroxide solvent system. Fractions 108124 were combined and evaporated to give gentamicin C2a (6) The pmr spectrum is shown in Fig. 1 and the cmr resonances in Table 2 .
Anal. Calcd. for C20H41N5O7 . 0.5 H2O: C, 50.83; H, 8.96 ; N, 14.82. Found: C, 50.54; H, 9.43; N, 14.60. 6'-N-t-Butoxycarbonylgentamicin C1a. To a stirred solution of gentamicin C1a (2.69 g, 6 mmole) in 50 % aqueous methanol containing triethylamine (1.82 ml), t-butoxycarbonyl azide (1.91 g, 13.4 mmole) was added with cooling to 5°C. After stirring for 18 hours at 5°C Amberlite IRA-401S ion-exchange resin (OH-cycle) was added and stirring continued for a further 30 minutes. The resin was removed by filtration and the filtrate concentrated to dryness in vacuo. The crude product was chromatographed over silica gel using the lower phase of system 3 ( Table 1) as eluant. Fractions were monitored by TLC and those containing the pure major product were pooled and lyophilized to give To a solution of 6'-N-t-butoxycarbonylgentamicin C1a (0.325g) in tetrahydrofuran lithium aluminum hydride (0.15g) was added. The mixture was heated under reflux with stirring and exclusion of moisture for 18 hours. After cooling to 10°C excess hydride was decomposed NO. 1 THE JOURNAL OF ANTIBIOTICS by addition of methanol, followed by water. The solution was acidified to pH 2 with hydrochloric acid and solids were removed by filtration through Celite. The filtrate was neutralized by addition of Amberlite IRA-401S resin (OH-cycle). After removal of the resin by filtration, 20 ml of Amberlite IRC-50 (H+ cycle) was added and the mixture stirred for 1 hour. The resin was separated, washed with water, and the product eluted with concentrated ammonium hydroxide. After concentration in ivacuo the product was chromatographed over silica gel (20 g) eluting with a chloroform-methanol-15 N ammonium hydroxide (2:1:0.35) solvent system. Two-ml fractions were collected and monitored by TLC. Fractions 45-49, containing the desired product, were pooled and lyophilized to give gentamicin C2n (0.075 g, 30 % ), [a]26D+ 147° (c, 0.38, H2O). The pmr, mass spectrum and chromatographic mobility of the product were identical to that of authentic gentamicin C2b.
